- Home
- SENS vs ALDX Comparison
SENS vs ALDX Comparison
Compare SENS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENS | ALDX |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.5M | 317.7M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SENS | ALDX |
|---|---|---|
| Price | $8.33 | $5.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $25.58 | $9.50 |
| AVG Volume (30 Days) | 464.3K | ★ 706.6K |
| Earning Date | 04-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,389,000.00 | N/A |
| Revenue This Year | $59.55 | N/A |
| Revenue Next Year | $69.13 | $36.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $0.41 | $1.18 |
| 52 Week High | $8.75 | $7.19 |
Technical Indicators
Market Signals| Indicator | SENS | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 63.80 | 59.87 |
| Support Level | $7.35 | $4.74 |
| Resistance Level | $8.74 | $5.75 |
| Average True Range (ATR) | 0.50 | 0.29 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 75.00 | 82.58 |
Price Performance
Historical ComparisonAbout SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.